Vyome Reports Sharp Reduction in Q3 2026 Loss Per Share; Advances Lead VT-1953 Program

CAMBRIDGE, Mass.–(BUSINESS WIRE)—- $HIND #biotechnology–Vyome Holdings, Inc. (Nasdaq: HIND, “Vyome” or the “Company”), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, reported financial results for the third quarter ended September 30, 2026, and provided a corporate update. Krishna Gupta, Chairman of Vyome Holdings, stated, “During the third quarter, Vyome continued to concentrate resources on the development of its lead program, VT-1953, while maintaining fina

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.